CalciMedica, Inc. reported its financial results for the year ended December 31, 2024, along with updates on its clinical and corporate activities. The company announced a net loss of $13.7 million for the full year 2024, a significant improvement compared to a net loss of $34.4 million for the year ended December 31, 2023. This reduction in net loss reflects improved financial management and operational efficiency.
Research and development expenses for 2024 were $14.5 million, a decrease from $15.9 million in 2023, while general and administrative expenses also saw a substantial reduction to $9.7 million from $22.2 million in the prior year. As of December 31, 2024, CalciMedica held $18.7 million in cash, cash equivalents, and short-term investments. With the proceeds from its recent credit facility, the company expects its cash position to fund operations into mid-2026.
Clinical updates included ongoing enrollment in the Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure, with data expected around the end of 2025. The company highlighted a post-hoc analysis of the Phase 2 CARDEA trial, which showed a 62.7% relative reduction in mortality for Auxora in a subset of AKI patients. CalciMedica plans an end-of-Phase 2 meeting with the FDA for its acute pancreatitis program, aiming to initiate a pivotal trial around the end of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.